Cloning and expression of human islet glutamic acid decarboxylase autoantigen
CA 2103159 A1 · Owner: The Board Of Regents Of The University Of Washington · Inventors: O'Hara, Patrick J.; Foster, Donald C.; Lernmark, Ake
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Human pancreatic islet cell glutamic acid decarboxylase (GAD) an, autoantigen involved in the development of insulin-dependent diabetes mellitus (IDDM), has been cloned sequenced and expressed, by recombinant means. Recombinant human islet cell GAD polypeptides and antibodies specific to the GAD polypeptides can be used in methods of diagnosis and treatment, including use in immunoadsorptive therapy and the induction of immune tolerance.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 14, 1992. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 14, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 14, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.